Kennedy Ferruggia, Associate Editor

Waters Corporation's Onclarity HPV Self-Collection Kit represents a significant advance in expanding access to cervical cancer screening outside the clinic.

The CDC testing pause disrupts diagnostic testing for infectious diseases like rabies and mpox, leaving pharmacists and states scrambling for answers.

The influenza vaccine halves the risk of heart attack and stroke after infection, offering cardiovascular protection even when breakthrough influenza occurs.

The National Association of Boards of Pharmacy (NABP) opens the door to the Occupational English Test (OET) as an alternative English exam for foreign pharmacy graduate certification.

Data from a new 20-year analysis reveal persistent inequities in influenza vaccination among a high-risk cardiovascular population.

Pulse by NABP is revolutionizing drug supply chain oversight and patient safety.

Fluvoxamine significantly reduced fatigue in adults with long COVID, with a 99% probability of outperforming placebo.

NABP weighs OET and best-section scoring to ease FPGEE path while boosting pass rates and safeguarding patient care.

Experts from NABP and the Arkansas State Board of Pharmacy explain how Pulse by NABP equips pharmacists and regulators with real-time drug supply chain verification tools.

Pharmacists' role in lipid management takes center stage with the 2026 dyslipidemia guideline update.

Learn how NABP’s FPGEC verifies foreign pharmacists and why TOEFL English proficiency standards remain central to US patient safety.

CDC flags a late respiratory syncytial virus (RSV) rise, while the NFID urges spring vigilance, vaccines, and monoclonals to protect infants and older adults from this virus.

A panel of neurology pharmacy specialists discusses the expanding clinical role of pharmacists in multiple sclerosis care.

Late-stage Lyme disease vaccine candidate VLA15 boosts immunization hopes as tick infections rise.

A new 2026 American Heart Association study shows COVID-19 infection sharply raises heart attack risk, whereas vaccination appears safe—key guidance for patient counseling.

Long-acting HIV injections and twice-yearly PrEP reshape care, while pharmacists tackle stigma, insurance hurdles, and adherence to close access gaps.

Nutrition coaching and pharmacist support boost medication adherence, tackle access barriers, and strengthen chronic disease routines.

This week's episode covers the court ruling halting RFK Jr.'s childhood vaccine schedule changes, the FDA's RSV vaccine approval for adults aged 18–49, pharmacist-led GLP-1 optimization strategies, and new gabapentin data in SUD treatment settings.

A timely pharmacist referral and collaborative care approach can set off a chain of positive lifestyle changes.

Icotrokinra, a first-in-class oral IL-23 receptor blocker, fills a long-standing gap in the treatment of moderate to severe plaque psoriasis.

Dual-target flu immunity to HA and NA halves airborne spread in ferrets without escape mutations, reshaping next-generation vaccines and pharmacist counseling.

Pharmacists play a pivotal role in helping patients align healthy nutritional habits with consistent medication adherence to improve long-term chronic disease outcomes.

New once-daily oral peptide blocks IL‑23 receptor, delivering high skin clearance and strong safety for moderate-to-severe plaque psoriasis in ages 12+.

The VIVID trial finds high-dose vitamin D3 doesn’t cut COVID care visits but hints at fewer long COVID symptoms.

Explore how pharmacists elevate electrophysiology care and get a preview of ACC 2026 trials on AF, HFpEF, pulmonary embolism, and hypertension.

Rapid RSV testing in pediatrics cuts unnecessary antibiotic use in young children with viral lung infections.

Ongoing measles outbreaks highlight the impacts of reduced vaccination rates and heightened public distrust in health experts.

Stable HCV E1E2 proteins on self-assembling nanoparticles spark strong mouse antibodies, advancing a long-sought hepatitis C vaccine.

A preclinical mucosal C difficile vaccine clears spores and prevents recurrence in animals, hinting at new protection for high‑risk patients.

The approval is significant for a condition that is estimated to affect fewer than 1 in 1 million individuals.